Hypothalamic peptide
Kisspeptin-10
Kisspeptin-10 has a plasma half-life of about 4 minutes in people, calculated at 3.8 to 4.1 minutes in one study; the app lists 0.07 hours.1
Kisspeptin-10 after one dose: 50% at ~4 min, 25% at 8 min, 12.5% at 12 min.
Drawn from the half-life in the app's model, ~4 min. The model's figures
- Compound
- Kisspeptin-10
- Symbol
- KP
- Family
- Growth hormone peptides
- Parts
- 13
- References
- 7
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Kisspeptin-10 is the 10-amino-acid form of the kisspeptin family of hypothalamic peptides, and the app describes it as the C-terminal decapeptide fragment of kisspeptin.2 George and colleagues, writing in the Journal of Clinical Endocrinology and Metabolism in 2011, called it "the minimal kisspeptin sequence with full intrinsic bioactivity" and described their studies as "first-in-human studies of kisspeptin-10".2 The human studies summarised below are small physiological experiments, mostly in healthy men, with between 3 and 10 participants in the cohorts that reported hormone results.3,4,2 No US drug label for kisspeptin was identified in DailyMed (search term "kisspeptin", 0 labels). The app grades the evidence for kisspeptin-10 as emerging.
How it works
Sources in this part
George and colleagues write that "Kisspeptins stimulate GnRH and thus gonadotropin secretion".2 The same authors note that "Kisspeptin signaling is obligatory for normal pubertal maturation, as evidenced by absent or advanced pubertal development in individuals with mutations in genes encoding kisspeptin".2 In their men given bolus and infusion kisspeptin-10, the authors state that systemic administration leaves open whether the rise in LH pulse frequency is mediated by a direct effect on GnRH neurons or through the hypothalamic pulse generator.2 Naveed and colleagues write that the kisspeptin receptor "does have a cytoplasmic tail, and its desensitization is mediated by classical G protein-coupled receptor mechanisms", a feature they contrast with the GnRH receptor.3 Whether continuous exposure reduces the response in people is unsettled in the sources: George and colleagues saw no tachyphylaxis over a 22.5 h infusion, whereas Naveed and colleagues saw LH decline by 13 to 47% from its maximum during a 24 h infusion.2,3
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~4 min
- Bioavailability
- 80%
- Typical dose
- 50–200 mcg/day
- Route
- SubQ
- Time to peak
- ~5 min
The second column holds the app's own figures, shown beside what the studies report.
| Parameter | App's figure | Reported in the studies |
|---|---|---|
| Half-life | ~4 min (0.07 h) | Plasma half-lives of 3.8 ± 0.3 min in men, 4.1 ± 0.4 min in follicular-phase women and 4.1 ± 0.4 min in preovulatory-phase women, from plasma kisspeptin immunoreactivity after an intravenous infusion of 360 pmol/kg/min in groups of 4 to 5; Jayasena and colleagues (2015) cite about 4 min for kisspeptin-10 against 27.6 min for kisspeptin-541,4 |
| Bioavailability | 80% | No subcutaneous bioavailability figure for kisspeptin-10 appears in the studies summarised here; the one subcutaneous bolus study in women reported plasma kisspeptin immunoreactivity that was "significantly elevated" for doses of 4 nmol/kg and higher, and the authors raise "breakdown of kisspeptin-10 in the sc tissue" as a possible explanation for the lack of hormone response1 |
| Time to peak | ~5 min (0.08 h) | After an intravenous bolus of 10 nmol/kg in men, "mean peak kisspeptin IR (3350 ± 725 pmol/liter) was observed 10 min after injection" and plasma immunoreactivity "returned to undetectable levels 50 min after injection"; serum LH peaked 30 to 40 min after injection, and serum testosterone, which was significantly increased only at the 0.3 and 1.0 nmol/kg doses, peaked 150 to 180 min after injection1 |
| Duration of action | 0.5 h | After the same intravenous bolus in men, serum LH "gradually returned to baseline 180 min after injection"1 |
| Route | SubQ | Jayasena and colleagues (2015) write that "kisspeptin-54 but not kisspeptin-10 can be administered subcutaneously due to its long half-life"; Yeung and colleagues (2026) infused kisspeptin-10 subcutaneously in healthy men and reported dose-dependent rises in LH, FSH and testosterone4,5 |
The peptide measured in plasma in these studies was detected by immunoassay (kisspeptin immunoreactivity), and George and colleagues note that "immunological assays can potentially give false-positive results in the presence of cleavage products of the peptide".2
Human studies
The app lists kisspeptin-10 under subcutaneous administration at 50 to 200 mcg/day; this figure is the app's own and is not taken from any of the studies below. The ClinicalTrials.gov search term "kisspeptin-10" returns 5 registry entries, and the human reports below come from PubMed records. No controlled trial of kisspeptin-10 in people with an outcome other than hormone levels was identified in PubMed or ClinicalTrials.gov in the searches run.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| George and colleagues, J Clin Endocrinol Metab 20112 | Dose-response and infusion studies, intravenous; funded by the Medical Research Council; authors report nothing to disclose2 | 6 healthy men (bolus study), 4 per infusion study; mean age 35.62 | Bolus 0.01 to 3.0 μg/kg; infusion 4 μg/kg/h for 22.5 h and 1.5 μg/kg/h for 9 h2 | Bolus: maximal LH rise at 1 μg/kg (4.1 ± 0.4 to 12.4 ± 1.7 IU/liter at 30 min); no significant LH rise at 3.0 μg/kg; testosterone unchanged by boluses. Infusion at 4 μg/kg/h: LH 5.4 ± 0.7 to 20.8 ± 4.9 IU/liter and testosterone 16.6 ± 2.4 to 24.0 ± 2.5 nmol/liter. No adverse events reported2 |
| Jayasena and colleagues, J Clin Endocrinol Metab 20111 | Five studies with intravenous bolus, subcutaneous bolus and intravenous infusion; funded by the Medical Research Council and others; authors report nothing to disclose1 | Healthy men and women, 4 to 5 per group1 | Intravenous bolus up to 10 nmol/kg; subcutaneous bolus up to 32 nmol/kg (women); infusion up to 720 pmol/kg/min (women)1 | Men: LH and FSH rose at doses as low as 0.3 and 1.0 nmol/kg. Women in the follicular phase: no change in gonadotropins after intravenous bolus, subcutaneous bolus or infusion. Women in the preovulatory phase: LH and FSH rose after 10 nmol/kg intravenously1 |
| Jayasena and colleagues, Human Reproduction 20154 | Single-blinded, placebo-controlled; kisspeptin-10, kisspeptin-54, GnRH and vehicle compared; funded by the MRC and NIHR4 | 10 healthy men aged 18 to 45 years, 5 per dose group4 | Intravenous 3 h infusions at 0.1, 0.3 and 1.0 nmol/kg/h4 | Kisspeptin-10 and kisspeptin-54 were associated with similar gonadotrophin secretion; GnRH was more potent. LH AUC at 1.0 nmol/kg/h: kisspeptin-10 10.81 ± 1.73, kisspeptin-54 14.43 ± 1.27, GnRH 34.06 ± 5.18 h.IU/l. Authors' limitation: small sample size4 |
| George and colleagues, Clinical Endocrinology 20136 | Proof-of-concept, intravenous bolus and infusion; grants listed from the Medical Research Council and NIA NIH HHS6 | 5 men with type 2 diabetes and low testosterone, and 7 age-matched healthy men6 | Bolus 0.3 mcg/kg; infusion 4 mcg/kg/h for 11 h in 4 men with diabetes6 | Bolus: LH rose in healthy men and in men with diabetes with comparable change. Infusion: LH rose from 3·9 ± 0·1 to 20·7 ± 1·1 IU/l and testosterone from 8·5 ± 1·0 to 11·4 ± 0·9 nmol/l6 |
| Yeung and colleagues, Eur J Endocrinol 20265 | Randomized, single-blinded, placebo-controlled; subcutaneous infusion5 | 15 healthy men recruited (studies of 7, 4 and 7); 12 served as controls5 | 1.25 to 10.0 nmol/kg/h for 8 h; 180 nmol/h continuously for 5 days; 150 nmol/h for 8 h daily for 12 days5 | Acute infusions dose-dependently raised LH, FSH and testosterone vs vehicle. After 5 days of continuous infusion testosterone stayed elevated but gonadotropins were similar to vehicle. With daily 8 h infusions mean LH increase was -0.16 ± 0.19 for vehicle, +1.68 ± 0.25 on day 1 and +1.14 ± 0.33 on day 12 (P = .003 vs vehicle)5 |
| Naveed and colleagues, Hormones (Athens) 20263 | Within-subject time-series physiologic experiment; intravenous; funded by grants from US federal bodies including NIH institutes and the FDA; senior author has a financial interest in SeNa Therapeutics3 | 3 healthy men aged 23 to 32 years3 | 12.5 mcg/kg/h intravenously for 24 h3 | LH rose from 2.8-3.8 to a maximum of 17.5-30.6 mIU/mL, then declined by 13-47% from maximum to end of infusion, which the authors describe as partial rather than complete attenuation; FSH and testosterone rose in parallel. No p-values calculated3 |
Deeper analysis: Jayasena 2011, kisspeptin-10 in men and women
Jayasena and colleagues at Imperial College London reported five studies of kisspeptin-10 in the Journal of Clinical Endocrinology and Metabolism in 2011.1 They gave intravenous boluses to men and women, a subcutaneous bolus and an intravenous infusion to women, and measured LH, FSH, estradiol in women or testosterone in men, and plasma kisspeptin immunoreactivity.1 In men, LH and FSH rose after intravenous kisspeptin-10, but testosterone changed little: "Significant increases in serum testosterone were observed only at 0.3 and 1.0 nmol/kg iv bolus kisspeptin-10, but these rises were marginal".1 In women in the follicular phase there was no hormone response by any route tested, even though plasma immunoreactivity was "significantly elevated" after the subcutaneous bolus and reached concentrations of up to 2000 pmol/liter during intravenous infusion.1 In the same women, kisspeptin-54 at 1 nmol/kg intravenously did raise gonadotropins, so the contrast was with the longer peptide.1 In the preovulatory phase, intravenous kisspeptin-10 at 10 nmol/kg raised LH and FSH, while estradiol was not significantly altered.1 The authors write that the lack of response to the subcutaneous bolus "may have been due to breakdown of kisspeptin-10 in the sc tissue", and that kisspeptin-10's rapid breakdown in the circulation may explain differences from kisspeptin-54.1 Their stated limitations include the possibility that subtle effects of kisspeptin-10 infusion on gonadotropin release were not detected, that tachyphylaxis at higher doses in men cannot be excluded, and that "Additional studies are required to investigate these observations".1 Funding included a Medical Research Council project grant, and the disclosure summary states that the authors have nothing to disclose.1 The methods state that "the presence of adverse symptoms" was recorded at regular intervals, and the paper's text gives no adverse event counts.1
Deeper analysis: George 2011, kisspeptin-10 boluses and infusions in men
George and colleagues at the Medical Research Council Human Reproductive Sciences Unit, Edinburgh, studied healthy men in the Journal of Clinical Endocrinology and Metabolism in 2011.2 The men's mean body mass index was 26.1 kg/m2, and the kisspeptin-10 was "custom synthesized under GMP standards".2 LH rose with bolus dose up to 1 μg/kg, and FSH also "increased dose dependently", but the 3 μg/kg bolus gave no significant LH rise.2 The authors call desensitization "a parsimonious explanation" but note it "has to be occurring rapidly after kisspeptin-10 administration before maximal stimulation of gonadotrophs is achieved", and they raise an alternative of action at another RF-amide receptor.2 During the 4 μg/kg/h infusion LH rose from 5.4 ± 0.7 to 20.8 ± 4.9 IU/liter and testosterone from 16.6 ± 2.4 to 24.0 ± 2.5 nmol/liter, but the FSH rise "was not statistically significant" and the change in pulse frequency was not significant (0.6 ± 0.1 to 0.8 ± 0.2 pulses/h).2 At the lower 1.5 μg/kg/h infusion in 4 men, mean LH rose from 5.2 ± 0.8 to 14.1 ± 1.7 IU/liter and pulse frequency from 0.7 ± 0.1 to 1.0 ± 0.2 pulses/h.2 A GnRH bolus during the infusion raised LH to a peak of 89.3 ± 6.1 IU/liter, which the authors report as "at least 2.5-fold greater in all subjects" than the peak LH after the kisspeptin-10 bolus.2 Limitations the authors describe include samples "not processed appropriately" so that kisspeptin immunoassays could not be run afterwards, and mass-spectrometry measurement of kisspeptin-10 and its cleavage products below the detection limit at almost all time points.2 The study was funded by a Medical Research Council grant, the disclosure summary says "The authors have nothing to disclose", and the paper reports "No adverse events were reported" alongside stable blood pressure, heart rate, liver and renal function, haemoglobin and electrolytes.2
Deeper analysis: Yeung 2026, subcutaneous kisspeptin-10 for up to 12 days
Yeung and colleagues at Imperial College London reported the study in the European Journal of Endocrinology in 2026, with Dhillo as last author.5 The authors state its aim as "to develop a protocol for chronic kisspeptin administration that persistently stimulates gonadotropin secretion".5 It combined an acute subcutaneous dose-response infusion, a 5-day continuous infusion and 12 days of daily 8 h infusions, with 15 healthy men recruited in total.5 The 5-day continuous infusion did not sustain gonadotropins: "testosterone concentrations remained elevated after 5 days of continuous kisspeptin-10, gonadotropin concentrations were similar to vehicle".5 The daily 8 h infusions "sustained increases in gonadotropins" over 12 days, with a mean LH increase of -0.16 ± 0.19 for vehicle, +1.68 ± 0.25 on day 1 and +1.14 ± 0.33 on day 12 (P = .003 vs vehicle), and a 1 nmol/kg bolus after 12 days still raised gonadotropins.5 The authors' conclusion is that "chronic subcutaneous kisspeptin administration sustains gonadotropin and testosterone secretion in healthy men for 12 days".5 Funding is listed as MRC and NIHR grants, and the conflict-of-interest statement says W.S.D. "has conducted consultancy work for AbCellera, KaNDy Therapeutics Ltd, and Myovant Sciences Ltd outside the submitted work" and A.A. for Myovant Sciences Ltd.5
Deeper analysis: Jayasena 2015, kisspeptin-10, kisspeptin-54 and GnRH compared
Jayasena and colleagues at Imperial College London compared the three peptides in 10 healthy men aged 18 to 45 years in Human Reproduction in 2015, with participants in a random order at least a week apart.4 At 1.0 nmol/kg/h the LH area under the curve was 10.81 ± 1.73 h.IU/l for kisspeptin-10, 14.43 ± 1.27 for kisspeptin-54 and 34.06 ± 5.18 for GnRH, and the authors report GnRH as about 3-fold higher than kisspeptin-10.4 The authors also state that for all three hormones peak levels of LH secretion were observed at the 0.3 nmol/kg/h dose.4 Plasma kisspeptin immunoreactivity at 1.0 nmol/kg/h was far lower with kisspeptin-10 (179 ± 24 h pmol/l) than with kisspeptin-54 (6650 ± 397), which the authors attribute to kisspeptin-10's much shorter half-life.4 The authors name the "small sample size" as a limitation, and write that "ethical considerations prohibited us from giving vehicle plus each of the three doses of each three tested hormones to individual subjects, which may have accounted for some of the observed variation in data".4 The funding statement names MRC and NIHR grants and fellowships; it lists no pharmaceutical sponsor.4 In the introduction the authors write that "Kisspeptin has been administered to human subjects without any significant acute or chronic adverse effects", a statement about kisspeptin in general; the paper's results report no adverse event counts for this study.4
Doses reported in studies and on labels
The app's typical dose is 50 to 200 mcg/day by the subcutaneous route, which is the app's own figure; Yeung and colleagues (2026) report 180 nmol/h for 5 days and 150 nmol/h for 8 h daily for 12 days.5 No label dose exists in the sources, since no US label for kisspeptin was identified, and the studies below report doses per kilogram or per hour rather than per day.
| Study | Route | Dose reported | People and length | Reference |
|---|---|---|---|---|
| George 2011, bolus | Intravenous bolus | 0.01 to 3.0 μg/kg, with vehicle | 6 healthy men, visits at least 1 week apart | 2 |
| George 2011, infusion | Intravenous infusion | 4 μg/kg/h for 22.5 h; 1.5 μg/kg/h for 9 h | 4 healthy men per infusion study | 2 |
| Jayasena 2011 | Intravenous bolus; subcutaneous bolus; intravenous infusion | Up to 10 nmol/kg; up to 32 nmol/kg; up to 720 pmol/kg/min | Men and women, 4 to 5 per group; 90 min infusions | 1 |
| Jayasena 2015 | Intravenous infusion | 0.1, 0.3 and 1.0 nmol/kg/h for 3 h | 10 healthy men, 5 per dose group | 4 |
| George 2013 | Intravenous bolus and infusion | 0.3 mcg/kg bolus; 4 mcg/kg/h for 11 h | 5 men with type 2 diabetes and 7 healthy men | 6 |
| Yeung 2026 | Subcutaneous infusion | 1.25 to 10.0 nmol/kg/h for 8 h; 180 nmol/h for 5 days; 150 nmol/h for 8 h daily for 12 days | 15 healthy men recruited | 5 |
| Naveed 2026 | Intravenous infusion | 12.5 mcg/kg/h (9.6 nmol/kg/h) for 24 h | 3 healthy men | 3 |
Side effects reported
George and colleagues reported "No adverse events were reported" in their 2011 studies of 6 men given boluses and 4 men per infusion study.2 Jayasena and colleagues (2011) recorded "adverse symptoms" at regular intervals but its text gives no counts, and the texts of Naveed and Jayasena (2015) give no adverse event counts either; the available records for Yeung and for George (2013) list none.1,5,6,3,4 Reduced or waning hormone responses are reported rather than a named adverse effect: a lower LH response at the 3 μg/kg bolus, and LH declining by 13 to 47% from its maximum during the 24 h infusion.2,3 Among the studies described above, the longest exposure to kisspeptin-10 was 12 days of daily 8 h subcutaneous infusions.5
Bloodwork and markers
The app lists LH, FSH and testosterone as the markers to monitor. In men, serum LH rose first after an intravenous bolus, peaking 30 to 40 min after injection, and the authors report LH rising "more potently and more rapidly than FSH".1 Testosterone responded later and less consistently after a bolus: it peaked 150 to 180 min after injection at the doses where it rose, and George and colleagues saw no significant testosterone change with any bolus dose.1,2 With longer infusions testosterone rose, for example from 16.6 ± 2.4 to 24.0 ± 2.5 nmol/liter over 22.5 h, and remained elevated after 5 days of continuous subcutaneous infusion while gonadotropin concentrations were similar to vehicle.2,5 In Jayasena and colleagues' 2015 men, the reference ranges used were LH 4 to 14 IU/l and FSH 1.5 to 8 IU/l, with baseline testosterone of 20.60 ± 2.03 nmol/l.4
Regulatory and anti-doping status
Sources in this part
The World Anti-Doping Agency's 2026 Prohibited List names "kisspeptin and its agonist analogues" under S2.2.1, testosterone-stimulating peptides in males.7 Section S2 is headed "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)", and the list does not name kisspeptin-10 separately.7 No US prescribing label for kisspeptin was identified in DailyMed (search term "kisspeptin", 0 labels).
What is not known
The app's 80% bioavailability has no matching figure in the studies summarised here; Jayasena and colleagues (2011) measured plasma kisspeptin immunoreactivity after subcutaneous bolus kisspeptin-10 in women but report no bioavailability figure.1 The studies give doses per kilogram or per hour, so whether the app's 50 to 200 mcg/day range matches any studied schedule is not stated in them. The one subcutaneous bolus study identified in women gave no hormone response in the follicular phase, and Yeung and colleagues studied subcutaneous infusion only in men.1,5 Jayasena and colleagues (2015) write that "we cannot exclude the possibility that subcutaneous bolus injection of kisspeptin-10 in other human models" such as preovulatory women or women with hypothalamic amenorrhoea could release gonadotrophins.4 Naveed and colleagues conclude that "it remains unclear whether prolonged exposure duration will attenuate kisspeptin receptor signaling in the eugonadal male".3 The studies summarised here measure hormone levels in small groups of up to 10 men or 4 to 5 women per cohort; clinical outcomes such as fertility or testosterone-related symptoms were not reported in them.4,1
Frequently asked questions
What is the half-life of kisspeptin-10?
Is kisspeptin-10 banned by WADA?
Is kisspeptin-10 FDA approved?
No US prescribing label for kisspeptin was identified in DailyMed (search term "kisspeptin", 0 labels).
What is kisspeptin-10?
Kisspeptin-10 is the 10-amino-acid C-terminal fragment of kisspeptin, described by George and colleagues as "the minimal kisspeptin sequence with full intrinsic bioactivity".2
Does kisspeptin-10 raise LH and testosterone in men?
Intravenous kisspeptin-10 raised LH in healthy men in several small studies, with a maximal bolus response at 1 μg/kg (4.1 ± 0.4 to 12.4 ± 1.7 IU/liter at 30 min) in 6 men.2 Testosterone did not change significantly with boluses in that study but rose during a 22.5 h infusion (16.6 ± 2.4 to 24.0 ± 2.5 nmol/liter, 4 men).2 At the highest bolus dose, 3.0 μg/kg, there was no significant increase in LH.2
Does subcutaneous kisspeptin-10 raise hormones in women?
Does kisspeptin-10 cause receptor desensitization?
In the 12-day subcutaneous work, part of a programme that recruited 15 healthy men across three studies, daily 8 h infusions "sustained increases in gonadotropins", while after a 5-day continuous infusion gonadotropin concentrations were similar to vehicle and testosterone stayed elevated.5 Over a 24 h intravenous infusion in 3 men, LH declined by 13 to 47% from its maximum.3 Naveed and colleagues describe partial rather than complete attenuation over the 24 h, and conclude that it remains unclear whether prolonged exposure duration will attenuate kisspeptin receptor signaling in the eugonadal male, while George and colleagues saw no tachyphylaxis over a 22.5 h infusion.3,2
How does kisspeptin-10 compare with kisspeptin-54 and GnRH?
At the doses tested in 10 healthy men, intravenous kisspeptin-10 and kisspeptin-54 were associated with similar gonadotrophin secretion, and GnRH was more potent than either.4
Guides, tools and comparisons
References
- Jayasena CN, et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab 2011;96(12):E1963-72. PMID 21976724
- George JT, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab 2011;96(8):E1228-36. PMID 21632807
- Naveed A, et al. Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men. Hormones (Athens) 2026. PMID 42230485
- Jayasena CN, et al. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Hum Reprod 2015;30(8):1934-41. PMID 26089302
- Yeung AC, et al. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. Eur J Endocrinol 2026;195(2):206-16. PMID 42549827
- George JT, et al. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clin Endocrinol (Oxf) 2013;79(1):100-4. PMID 23153270
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list